Table 3.

Univariable and multivariable analyses of factors associated with death and relapse for the entire Registry cohort of 727 granulomatosis with polyangiitis patients

Factor	Death				Relapse
	Univariable analysis		Multivariable analysis		Univariable analysis		Multivariable analysis
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age	1.07 (1.04 to 1.09)	<0.001	1.07 (1.04 to 1.09)	<0.001	0.99 (0.99 to 1.00)	0.520
Female	0.64 (0.37 to 1.08)	0.09			1.03 (0.78 to 1.19)	0.773
Lung	0.46 (0.88 to 2.90)	0.123			0.98 (0.78 to 1.22)	0.864
Alveolar haemorrhage	2.14 (1.23 to 3.72)	0.006			1.08 (0.83 to 1.42)	0.547
Renal	3.19 (1.77 to 5.79)	0.0001			1.02 (0.83 to 1.26)	0.827
Serum creatinine >150 µmol/L	2.16 (1.24 to 3.76)	0.006			0.92 (0.70 to 1.21)	0.572
Skin	1.42 (0.84 to 2.40)	0.180			1.04 (0.83 to 1.29)	0.734
Ear, nose and throat	0.77 (0.42 to 1.41)	0.409			1.12 (0.86 to 1.47)	0.396
Eye	0.75 (0.42 to 1.34)	0.347			1.02 (0.81 to 1.28)	0.826
Cardiovascular	2.70 (1.56 to 4.70)	0.0004			1.06 (0.80 to 1.42)	0.653
Congestive heart failure	10.73 (4.56 to 25.22)	<0.0001	3.20 (1.12 to 9.16)	0.029	0.69 (0.22 to 2.14)	0.521
Gastrointestinal	1.27 (0.54 to 2.97)	0.571			0.97 (0.67 to 1.41)	0.905
Neurological	1.61 (0.96 to 2.69)	0.067			0.98 (0.78 to 1.24)	0.926
BVAS	1.07 (1.04 to 1.10)	<0.001			0.99 (0.98 to 1.00)	0.283
Anti-myeloperoxidase	2.25 (1.28 to 3.94)	0.004			0.82 (0.60 to 1.12)	0.219
Anti-proteinase-3	0.51 (0.30 to 0.85)	0.01	0.43 (0.18 to 1.03)	0.060	1.31 (1.01 to 1.69)	0.040	1.29 (1.00 to 1.68)	0.047
ANCA negative	1.04 (0.47 to 2.29)	0.921			0.76 (0.51 to 1.13)	0.185
Intravenous CYC	–	–			0.85 (0.66 to 1.10)	0.232
Oral CYC	–	–			0.63 (0.37 to 1.07)	0.091
Rituximab	–	–			0.77 (0.43 to 1.38)	0.385
Methotrexate	–	–			1.02 (0.63 to 1.65)	0.912

ANCA, antineutrophil cytoplasm antibody; BVAS, Birmingham Vasculitis Activity Score.